Literature DB >> 25456941

Reappraisal of lymphatic mapping for midgut neuroendocrine patients undergoing cytoreductive surgery.

Yi-Zarn Wang1, Jean P Carrasquillo1, Elizabeth McCord2, Rhea Vidrine1, Monica L Lobo1, S Ali Zamin1, Philip Boudreaux1, Eugene Woltering1.   

Abstract

BACKGROUND: We previously reported that midgut neuroendocrine tumors (NETs) often develop alternative lymphatic drainage owing to lymphatic obstructions from extensive mesenteric lymphadenopathy, making intraoperative lymphatic mapping mandatory. We hypothesize that this innovative approach needs a longer term validation.
METHODS: We updated our results by reviewing 303 patients who underwent cytoreduction from November 2006 to October 2011. Of these patients, 112 had lymphatic mappings and 98 were for midgut NET primaries. Among them, 77 mappings were for the initial cytoreduction and 35 were for reexploration and further cytoreduction. The operative findings, pathology reports, and long-term surgical outcomes were reviewed.
RESULTS: Lymphatic mapping changed traditional resection margins in 92% of patients. Of the 35 patients who underwent reexploration without initial mapping, 19 (54%) showed a recurrence at or near the anastomotic sites. In contrast, none of the 112 mapped patients had shown signs of recurrence in a 1- to 5-year follow-up. Additionally, 20 of 45 ileocecal valves (44.4%) were spared in patients whose tumors were at the terminal ileum that, traditionally, would call for a right hemicolectomy.
CONCLUSION: With a longer follow-up, lymphatic mapping has proven to be a safe and effective way to prevent local recurrences and preserve the ileocecal valve for selected patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25456941     DOI: 10.1016/j.surg.2014.05.028

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

Review 1.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

2.  The Number of Lymph Nodes Examined is Associated with Survival Outcomes of Neuroendocrine Tumors of the Jejunum and Ileum (siNET): Development and Validation of a Prognostic Model Based on SEER Database.

Authors:  Peng Wang; Erlin Chen; Mingjie Xie; Wei Xu; Chaoyang Ou; Zhou Zhou; Yuanjie Niu; Wei Song; Qingfeng Ni; Jianwei Zhu
Journal:  J Gastrointest Surg       Date:  2022-06-10       Impact factor: 3.267

Review 3.  Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.

Authors:  Julie Hallet; Calvin Law
Journal:  World J Surg       Date:  2020-07-31       Impact factor: 3.352

4.  Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine.

Authors:  Erik Elias; Arman Ardalan; Markus Lindberg; Susanne E Reinsbach; Andreas Muth; Ola Nilsson; Yvonne Arvidsson; Erik Larsson
Journal:  Nat Commun       Date:  2021-11-04       Impact factor: 14.919

5.  Vessel-Sparing Lymphadenectomy Should Be Performed in Small Intestine Neuroendocrine Neoplasms.

Authors:  Detlef K Bartsch; Sebastian Windel; Veit Kanngießer; Moritz Jesinghaus; Katharina Holzer; Anja Rinke; Elisabeth Maurer
Journal:  Cancers (Basel)       Date:  2022-07-25       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.